What does the cutting edge of radiation oncology look like for treating triple-negative breast cancer? Tune in to hear experts Drs Kevin Kalinsky and Reshma Jagsi discuss.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
A Review of Triple-negative Breast Cancer https://www.medscape.com/viewarticle/727195_4
A Review of the Abscopal Effect in the Era of Immunotherapy https://pubmed.ncbi.nlm.nih.gov/36321062/
The Impact of Radiation-induced DNA Damage on cGAS-STING-mediated Immune Responses to Cancer https://pubmed.ncbi.nlm.nih.gov/33238631/
Gray (Gy) https://www.nrc.gov/reading-rm/basic-ref/glossary/gray-gy.html
Event-free Survival With Pembrolizumab in Early Triple-negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/35139274/
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-negative Breast Cancer https://clinicaltrials.gov/study/NCT02954874
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) https://clinicaltrials.gov/study/NCT04443348
Translational Breast Cancer Research Consortium (TBCRC) https://tbcrc.org/
Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/34900718/
SWOG Cancer Research Network https://www.swog.org/
BRCA1 and BRCA2 Mutations https://www.ncbi.nlm.nih.gov/books/NBK470239/
Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study https://pubmed.ncbi.nlm.nih.gov/29558281/
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer https://clinicaltrials.gov/study/NCT03598257
Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview
ER/PgR Testing in Breast Cancer Clinical Practice Guidelines (ASCO/CAP, 2020) https://reference.medscape.com/viewarticle/924542
Oncotype DX Breast Recurrence Score®: A Review of Its Use in Early-stage Breast Cancer https://pubmed.ncbi.nlm.nih.gov/32613290/
Regional Radiotherapy in Biomarker Low-risk Node Positive and T3N0 Breast Cancer (TAILOR RT) https://classic.clinicaltrials.gov/ct2/show/NCT03488693
Postoperative Radiotherapy in High-risk Premenopausal Women With Breast Cancer Who Receive Adjuvant Chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial https://pubmed.ncbi.nlm.nih.gov/9395428/
Postoperative Radiotherapy in High-risk Postmenopausal Breast-cancer Patients Given Adjuvant Tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c Randomised Trial https://pubmed.ncbi.nlm.nih.gov/10335782/
Risk of Ischemic Heart Disease in Women After Radiotherapy for Breast Cancer https://pubmed.ncbi.nlm.nih.gov/23484825/
Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-risk, Node-positive Breast Cancer Enrolled in the SWOG S1007 Trial https://pubmed.ncbi.nlm.nih.gov/37410451/